VolitionRx study validates Nu.Q NETs H3.1 biomarker as predictor of 28-day sepsis mortality, RRT need - VNRX News | RalliesVolitionRx study validates Nu.Q NETs H3.1 biomarker as predictor of 28-day sepsis mortality, RRT need
V
VNRX• Peer-reviewed validation for Nu.Q NETs H3.1
- VolitionRx reported peer-reviewed clinical validation for its Nu.Q NETs H3.1 sepsis biomarker, published in Critical Care Medicine.
- Results were presented via publication, not flagged for a future conference readout.
- The study concluded the biomarker can independently flag higher-risk sepsis patients, supporting earlier clinical decisions on organ support.
- Management said the data strengthen licensing talks with diagnostics partners across a sepsis market it sizes at USD 2.8 billion.
